Elicio Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Elicio Therapeutics

29/03/2024 13:46

* Elicio Therapeutics Inc  ELTX.OQ  reported a quarterly
adjusted
loss of $1.75​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-2.10.  The mean expectation of two analysts
for the quarter was for a loss of 78 cents per share. Wall
Street expected results to range from $-1.03 to -54 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Elicio Therapeutics Inc's reported EPS for the quarter was
a
loss of $1.75​.
    * The company reported a quarterly loss of $8.95 million.
    * Elicio Therapeutics Inc shares had fallen by 10.6% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 14.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "hold."

Wall Street's median 12-month price target for Elicio
Therapeutics Inc is $11.00 
This summary was machine generated from LSEG data March 29 at
01:46 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.78          -1.75          Missed
 Sep. 30 2023      -0.80          -1.27          Missed
                                  -2.44          
                                  -1.50